Thais M. C.
- Country
- Spain
- Department
- Pediatric Oncology
Research Overview
- Asciminib in Pediatric Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase With or Without T315I Mutation: Phase II Safety and Efficacy Study
- Phase 3 Study of Imatinib with Cytotoxic Chemotherapy in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Efficacy and Safety Evaluation of Mitapivat in Pediatric Patients with Pyruvate Kinase Deficiency Not Receiving Regular Transfusions: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 40 of 174 partner sites.
Specializations
Pediatric Hematology
This investigator specializes in treating rare blood disorders affecting pediatric populations, with particular emphasis on Pyruvate Kinase Deficiency management strategies.
- Transfusion-dependent PK Deficiency
- Non-transfusion-dependent PK Deficiency
- Hemoglobin concentration management
The research focus includes innovative therapeutic approaches for both transfusion-dependent and independent young patients.
Rare Blood Disorders
The investigator demonstrates expertise in treating Paroxysmal Nocturnal Hemoglobinuria in adolescent patients, examining novel therapeutic interventions.
- Adolescent PNH treatment
- Hemolysis management
- Complement inhibition therapy
Special attention is given to monitoring treatment safety and biological responses in young patients with rare hematological conditions.
Clinical Pharmacology
The investigator focuses on evaluating novel therapeutic agents for rare hematological disorders, including pharmacokinetic studies in adolescent populations.
- Drug efficacy assessment
- Safety monitoring
- Biological response markers
Research interests include measuring treatment outcomes through multiple clinical parameters and biomarkers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.